Open AccessRapid Lipid Modification of Endothelial Cell Membranes in Cardiac Ischemia/Reperfusion Injury: a Novel Therapeutic Strategy to Reduce Infarct Size
Author(s) -
Claudio Maldonado,
Mai-Dung Nguyen,
Phillip Bauer,
Shunichi Nakamura,
Syed Jalal Khundmiri,
Gustavo Perez-Abadía,
Heather Stowers,
Wenjian Wu,
Xian Liang Tang
Publication year - 2020
Publication title -
cardiovascular drugs and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 69
eISSN - 1573-7241
pISSN - 0920-3206
DOI - 10.1007/s10557-020-07101-x
Subject(s) - medicine , reperfusion injury , myocardial infarction , cardiology , troponin i , ischemia , percutaneous coronary intervention , conventional pci , cardioprotection , pharmacology
Plasma membranes constitute a gathering point for lipids and signaling proteins. Lipids are known to regulate the location and activity of signaling proteins under physiological and pathophysiological conditions. Membrane lipid therapies (MLTs) that gradually modify lipid content of plasma membranes have been developed to treat chronic disease; however, no MLTs have been developed to treat acute conditions such as reperfusion injury following myocardial infarction (MI) and percutaneous coronary intervention (PCI). A fusogenic nanoliposome (FNL) that rapidly incorporates exogenous unsaturated lipids into endothelial cell (EC) membranes was developed to attenuate reperfusion-induced protein signaling. We hypothesized that administration of intracoronary (IC) FNL-MLT interferes with EC membrane protein signaling, leading to reduced microvascular dysfunction and infarct size (IS).